ACY-738 (C09-0735-581)

InformationACY-738 inhibitsHDAC6with low nanomolar potency (IC50=1.7 nM) and a selectivity of 60- to 1500-fold over class I HDACs.TargetsHDAC6 (Cell-free) 1.7 nMIn vivoACY-738 induces dramatic increases in α-tubulin acetylation in brain and stimulate mouse exploratory behaviors in novel, but not familiar environments. ACY-738 has the antidepressant-like properties. Elimination of ACY-738 from plasma is rapid, with plasmatic half-life of 12/u2009min and concentration below 10/u2009ng/ml after 2/u2009h. ACY-738 rapidly distributes to the brain leading to a total drug exposure in CNS comparable to that of peripheral tissues. ACY-738 decreases several characteristics of SLE (Systemic lupus erythematosus) in NZB/W mice by dictating B cell development in the bone marrow. ACY-738 treatment increases the percentage of B cells in early developmental stages, while decreasing the percentage of cells in late pre-B cell fraction F. ACY-738 regulation of BM B cell development could be due to regulation developmental checkpoints known to be dysfunctional during SLE.Cell Research(from reference)Cell lines：Undifferentiated RN46A-B14 cells Concentrations：2.5/u2009μM Incubation Time：4 h. Specification: 0.99 Molecular Formula: C14H14N4O2 Molecular Weight: 270.29 PubChem CID: 57381425 Isomeric SMILES: C1CC1(C2=CC=CC=C2)NC3=NC=C(C=N3)C(=O)NO Related Documents: https://ald-pub-files.oss-cn-shanghai.aliyuncs.com/aladdinsci/pdp/sds/1/A414096-SCI_8f757c13ade690802f90e2d98c6019f5.pdf